[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.173.184. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
September 15, 2015

Immune Checkpoint Blockade in Cancer TherapyThe 2015 Lasker-DeBakey Clinical Medical Research Award

Author Affiliations
  • 1Department of Immunology and Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas
JAMA. 2015;314(11):1113-1114. doi:10.1001/jama.2015.11929

The 2015 Lasker-DeBakey Clinical Medical Research Award has been presented to James P. Allison, PhD, for pioneering work in enabling T cells of the immune system to attack cancer cells by removing “checkpoints” that normally inhibit T-cell activity. This Viewpoint provides a summary of these discoveries involving regulation of the T-cell response, development of immune checkpoint blockade in cancer therapy, and implications of engaging the immune response as a new modality for cancer treatment.

First Page Preview View Large
First page PDF preview
First page PDF preview
×